1. N6-methyladenosine triggers renal fibrosis via enhancing translation and stability of ZEB2 mRNA.
- Author
-
Cai Y, Zhou J, Xu A, Huang J, Zhang H, Xie G, Zhong K, Wu Y, Ye P, Wang H, and Niu H
- Subjects
- Humans, Animals, Mice, RNA-Binding Proteins metabolism, RNA-Binding Proteins genetics, Protein Biosynthesis, Kidney Diseases metabolism, Kidney Diseases genetics, Kidney Diseases pathology, Male, Kidney metabolism, Kidney pathology, Zinc Finger E-box Binding Homeobox 2 metabolism, Zinc Finger E-box Binding Homeobox 2 genetics, Adenosine analogs & derivatives, Adenosine metabolism, Fibrosis, Epithelial-Mesenchymal Transition, RNA, Messenger genetics, RNA, Messenger metabolism, RNA Stability
- Abstract
In recent years, a surge in studies investigating N6-methyladenosine (m
6 A) modification in human diseases has occurred. However, the specific roles and mechanisms of m6 A in kidney disease remain incompletely understood. This study revealed that m6 A plays a positive role in regulating renal fibrosis (RF) by inducing epithelial-to-mesenchymal phenotypic transition (EMT) in renal tubular cells. Through comprehensive analyses, including m6 A sequencing, RNA-seq, and functional studies, we confirmed the pivotal involvement of zinc finger E-box binding homeobox 2 (ZEB2) in m6 A-mediated RF and EMT. Notably, the m6 A-modified coding sequence of ZEB2 mRNA significantly enhances its translational elongation and mRNA stability by interacting with the YTHDF1/eEF-2 complex and IGF2BP3, respectively. Moreover, targeted demethylation of ZEB2 mRNA using the dm6 ACRISPR system substantially decreases ZEB2 expression and disrupts the EMT process in renal tubular epithelial cells. In vivo and clinical data further support the positive influence of m6 A/ZEB2 on RF progression. Our findings highlight the m6 A-mediated regulation of RF through ZEB2, revealing a novel therapeutic target for RF treatment and enhancing our understanding of the impact of mRNA methylation on kidney disease., Competing Interests: Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF